AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16019621 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 346
Study 12447213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovate pontic design with Super Floss cleaning once a day
Number of subjects: 12
Study 12447213 — intervention group
Group type: COMPARATOR
Intervention: Control site (uncovered masticatory mucosal area)
Number of subjects: 12
Study 12447213 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovate pontic design
Number of subjects: 12
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BKCI)
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS)
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Triethanolamine (TEA)
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tween 80
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: BKCI, SLS, and Tween 80 (suction blister fluids)
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: BKCI and SLS
Number of subjects: 0
Study 9875300 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 alpha
Number of subjects: 0
Study 8544154 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso-osmotic bowel preparation (Klean Prep)
Number of subjects: 56
Study 8544154 — intervention group
Group type: COMPARATOR
Intervention: 12 h starvation
Number of subjects: 56
Study 2096198 — intervention group
Group type: EXPERIMENTAL
Intervention: KCl (75 mmol/day)
Number of subjects: 24
Study 2096198 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (75 mmol/day)
Number of subjects: 24
Study 2096198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 341949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 341949 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 341949 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 28851508 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term housing subsidies
Number of subjects: 1857
Study 28851508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no immediate referral to any intervention)
Number of subjects: 1857
Study 28851508 — intervention group
Group type: EXPERIMENTAL
Intervention: SSI/SSDI receipt
Number of subjects: 1857
Study 28851508 — intervention group
Group type: EXPERIMENTAL
Intervention: Disabilities
Number of subjects: 1857
Study 27365261 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality using the Nintendo Wii gaming system (VRWii)
Number of subjects: 141
Study 27365261 — intervention group
Group type: COMPARATOR
Intervention: Recreational activities (playing cards, bingo, Jenga, or ball game)
Number of subjects: 141
Study 24662398 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab 140 mg Q2 W
Number of subjects: 310
Study 24662398 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab 420 mg QM
Number of subjects: 310
Study 24662398 — intervention group
Group type: COMPARATOR
Intervention: placebo Q2 W or QM
Number of subjects: 310
Study 24662398 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab
Number of subjects: 310
Study 24662398 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 310
Study 23381198 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1000 mg intravenously during anesthesia induction)
Number of subjects: 30
Study 23381198 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid administration)
Number of subjects: 30
Study 19967328 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone spray
Number of subjects: 0
Study 19967328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18500478 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15893523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing language for spatial relations
Number of subjects: 0
Study 15893523 — intervention group
Group type: COMPARATOR
Intervention: Initial exposure to spatial terms
Number of subjects: 0
Study 12952498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg with centchroman 30 mg
Number of subjects: 22
Study 12952498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg, centchroman 30 mg, and lactic acid bacillus spores (60 million)
Number of subjects: 22
Study 12952498 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously reported data)
Number of subjects: 22
Study 10647760 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/d), possibly with captopril (12.5-50 mg/d) and/or hydrochlorothiazide (12.5-50 mg/d)
Number of subjects: 1253
Study 10647760 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 1253
Study 10647760 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 1253
Study 8678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 180
Study 8678101 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 180
Study 8678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftazidime
Number of subjects: 180
Study 2057034 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg per day)
Number of subjects: 2569
Study 2057034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2569
Study 6951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat
Number of subjects: 132
Study 6951261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector
Number of subjects: 132
Study 6951261 — intervention group
Group type: COMPARATOR
Intervention: Control side (Duraphat)
Number of subjects: 132
Study 6951261 — intervention group
Group type: COMPARATOR
Intervention: Control side (Fluor Protector)
Number of subjects: 132
Study 31577394 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group self-compassion-based intervention (1-hour sessions once per week)
Number of subjects: 8
Study 30152428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise during the first 2 hours of HD
Number of subjects: 20
Study 30152428 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 20
Study 26945741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% A/BPO
Number of subjects: 503
Study 26945741 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 503
Study 26945741 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% A/BPO
Number of subjects: 503
Study 24863570 — intervention group
Group type: COMPARATOR
Intervention: targeted ultraviolet B (tUVB) treatment
Number of subjects: 11
Study 24863570 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 11
Study 22215413 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic group (instructed to produce sequences according to a rule of their choice)
Number of subjects: 0
Study 22215413 — intervention group
Group type: EXPERIMENTAL
Intervention: Random group (instructed to produce sequences according to chance)
Number of subjects: 0
Study 22215413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not instructed about how to produce sequences)
Number of subjects: 0
Study 22215413 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups during extinction phase (B phase)
Number of subjects: 0
Study 22215413 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic group
Number of subjects: 0
Study 20930354 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.074% diclofenac mouthwash
Number of subjects: 20
Study 20930354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18588441 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 60
Study 18588441 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (control)
Number of subjects: 60
Study 18588441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16091074 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 56
Study 16091074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 56
Study 16091074 — intervention group
Group type: COMPARATOR
Intervention: Overall (Morphine vs Pethidine)
Number of subjects: 56
Study 12418063 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling using a harmonic scalpel (Group A)
Number of subjects: 34
Study 12418063 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling using a neodymium‐yttrium‐aluminum‐garnet laser (Group B)
Number of subjects: 34
Study 11956045 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress phase (final examination week)
Number of subjects: 20
Study 11956045 — intervention group
Group type: COMPARATOR
Intervention: Low-stress phase (midsemester or two weeks postfinal examination)
Number of subjects: 20
Study 9707384 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate (LAAM) high-dose (100 mg) induction lasting 17 days
Number of subjects: 180
Study 9707384 — intervention group
Group type: COMPARATOR
Intervention: Levomethadyl acetate (LAAM) low-dose (25 mg) induction
Number of subjects: 180
Study 9707384 — intervention group
Group type: COMPARATOR
Intervention: Levomethadyl acetate (LAAM) medium-dose (50 mg) induction lasting 7 days
Number of subjects: 180
Study 7713467 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme combination preparation
Number of subjects: 192
Study 7713467 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 192
Study 2495779 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times a day)
Number of subjects: 239
Study 2495779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 761334 — intervention group
Group type: EXPERIMENTAL
Intervention: Reorganized treatment group
Number of subjects: 202
Study 761334 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treatment group
Number of subjects: 202
Study 761334 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone alone
Number of subjects: 202
Study 31634108 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Health Improvement Program (CHIP) for 9 months
Number of subjects: 120
Study 31634108 — intervention group
Group type: COMPARATOR
Intervention: Healthy Heart program for 9 months
Number of subjects: 120
Study 26825447 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 at 3000 ppm with bioeffluents
Number of subjects: 25
Study 26825447 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 at 1000 ppm with bioeffluents
Number of subjects: 25
Study 26825447 — intervention group
Group type: COMPARATOR
Intervention: CO2 at 500 ppm (reference condition)
Number of subjects: 25
Study 25746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring 16 patients
Number of subjects: 42
Study 25746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring 24 patients
Number of subjects: 42
Study 25746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring 32 patients
Number of subjects: 42
Study 25746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring 40 patients
Number of subjects: 42
Study 25746509 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring 48 patients
Number of subjects: 42
Study 23406077 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 nitrous oxide and oxygen at 9 L/min (N(2) O group)
Number of subjects: 60
Study 23406077 — intervention group
Group type: COMPARATOR
Intervention: Medical air at 9 L/min (MA group)
Number of subjects: 60
Study 21224456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (pelvic floor muscle training and bladder control strategies)
Number of subjects: 208
Study 21224456 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy plus biofeedback and pelvic floor electrical stimulation
Number of subjects: 208
Study 21224456 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 208
Study 19948277 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy
Number of subjects: 0
Study 17174113 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (2 weeks)
Number of subjects: 49
Study 17174113 — intervention group
Group type: COMPARATOR
Intervention: Late mobilization (6 weeks)
Number of subjects: 49
Study 15520341 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHENA program (8 weekly 45-minute sessions)
Number of subjects: 928
Study 11739067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 116
Study 11739067 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 116
Study 9234827 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil
Number of subjects: 303
Study 9234827 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mibefradil
Number of subjects: 303
Study 9234827 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg mibefradil
Number of subjects: 303
Study 9234827 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mibefradil
Number of subjects: 303
Study 9234827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 7962680 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine treatment
Number of subjects: 0
Study 3596358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3596358 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of aspirin
Number of subjects: 17
Study 3596358 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin
Number of subjects: 17
Study 28953493 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lozenges (40 mg) administered 30 minutes preoperatively
Number of subjects: 79
Study 28953493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 26589105 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment in patients with obesity (twice-daily for 20-52 weeks)
Number of subjects: 713
Study 26589105 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin treatment in patients with lipodystrophy (once-daily or twice-daily for 2 months to 12.3 years)
Number of subjects: 713
Study 26589105 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro neutralizing activity in patients with obesity
Number of subjects: 713
Study 26589105 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro neutralizing activity in patients with lipodystrophy
Number of subjects: 713
Study 25003738 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger pouches
Number of subjects: 97
Study 25003738 — intervention group
Group type: COMPARATOR
Intervention: Smaller pouches
Number of subjects: 97
Study 23190837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban (10 mg) once daily for 10 days, starting 6 to 8 hours after surgery
Number of subjects: 40
Study 23190837 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo once daily for 10 days, starting 6 to 8 hours after surgery
Number of subjects: 40
Study 20160653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamins (2 g vitamin C and 800 IU vitamin E)
Number of subjects: 88
Study 20160653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20160653 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine loading (100 mg/kg body weight)
Number of subjects: 88
Study 20160653 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine loading
Number of subjects: 88
Study 18515689 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (PST)
Number of subjects: 206
Study 18515689 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 206
Study 16036895 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous bubbling for 30 minutes
Number of subjects: 26
Study 16036895 — intervention group
Group type: EXPERIMENTAL
Intervention: High amplitude bubbling for 30 minutes
Number of subjects: 26
Study 16036895 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow bubbling for 30 minutes
Number of subjects: 26
Study 14622687 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg etoricoxib
Number of subjects: 319
Study 14622687 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 319
Study 14622687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 10742934 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month, manual-based, psychoeducational family therapy
Number of subjects: 0
Study 10742934 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' ratings of participants' problem behaviors
Number of subjects: 0
Study 10742934 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent observers' ratings of overall treatment difficulty
Number of subjects: 0
Study 9003103 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgG or IgM)
Number of subjects: 570
Study 9003103 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (IgA)
Number of subjects: 570
Study 1728527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA (2 g/day)
Number of subjects: 44
Study 1728527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6093236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low secretory IgA concentrations in IM patients, mean value 0.180 g/l
Number of subjects: 18
Study 6093236 — intervention group
Group type: COMPARATOR
Intervention: Tinidazole treatment
Number of subjects: 18
Study 2942457 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% foscarnet cream for men
Number of subjects: 230
Study 2942457 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% foscarnet cream for women
Number of subjects: 230
Study 2942457 — intervention group
Group type: EXPERIMENTAL
Intervention: foscarnet cream (both dosages)
Number of subjects: 230
Study 2942457 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 230
Study 31532835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose and music
Number of subjects: 16
Study 31532835 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 16
Study 28993963 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and EPA supplementation for 3 months
Number of subjects: 162
Study 28993963 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 162
Study 27854537 — intervention group
Group type: EXPERIMENTAL
Intervention: New physical activity standards in South Carolina
Number of subjects: 64
Study 26528650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with SZO/SA
Number of subjects: 46
Study 26528650 — intervention group
Group type: COMPARATOR
Intervention: NHANES users of MHS
Number of subjects: 46
Study 26528650 — intervention group
Group type: COMPARATOR
Intervention: NHANES nonusers of MHS
Number of subjects: 46
Study 24172558 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal incision (von Noorden)
Number of subjects: 24
Study 24172558 — intervention group
Group type: COMPARATOR
Intervention: Para limbal incision (Santiago)
Number of subjects: 24
Study 20495161 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (Concerta)
Number of subjects: 53
Study 20495161 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (IR-MPH)
Number of subjects: 53
Study 18501061 — intervention group
Group type: COMPARATOR
Intervention: Calcium-rich diet (CA)
Number of subjects: 90
Study 18501061 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-rich diet + exercise (CA + EX)
Number of subjects: 90
Study 18501061 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-rich diet + exercise and high fruit and vegetable, low-fat diet (CA + EX + FVLF)
Number of subjects: 90
Study 16929448 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative epoetin-alpha treatment added to standard care
Number of subjects: 695
Study 16929448 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 695
Study 11756667 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (1 mg)
Number of subjects: 10
Study 11756667 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg)
Number of subjects: 10
Study 11756667 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (placebo)
Number of subjects: 10
Study 9789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melimmune-1 and Melimmune-2 administered with SAF-m adjuvant
Number of subjects: 21
Study 9789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melimmune-1
Number of subjects: 21
Study 9789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melimmune-2
Number of subjects: 21
Study 9789200 — intervention group
Group type: EXPERIMENTAL
Intervention: Melimmune-1 and/or Melimmune-2 F(Ab')2
Number of subjects: 21
Study 7694970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 70
Study 7694970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 7694970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (after 12 months)
Number of subjects: 70
Study 7694970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin and Placebo (both groups)
Number of subjects: 70
Study 2703174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary irradiation using high dose-rate afterloading technique with 60Co sources
Number of subjects: 366
Study 2703174 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 366
Study 2703174 — intervention group
Group type: COMPARATOR
Intervention: 5 Gy per fraction
Number of subjects: 366
Study 2703174 — intervention group
Group type: COMPARATOR
Intervention: 10 Gy per fraction
Number of subjects: 366
Study 2703174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (hysterectomy and radiotherapy)
Number of subjects: 366
Study 2703174 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy group
Number of subjects: 366
Study 342631 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent (A/New Jersey/76) vaccine, single dose
Number of subjects: 444